|
|
|
|
|
|
|
28.05.25 - 15:45
|
Spero Therapeutics-Aktie +300%: Jubelsturm bei NBC-Anlegern! (Sharedeals)
|
|
|
Ein Tag, der in die Annalen des exklusiven No Brainer Club (NBC) eingehen wird: Aus dem Nichts schießt die Aktie des Biotech-Unternehmens Spero Therapeutics nach positiven Daten-News vorbörslich um bis zu +300% durch die Decke und kurz darauf zündet noch eine weitere Kursrakete. Der Jubel im Anlegerkreis kennt keine Grenzen mehr! Wirkstoff Tebipenem vor Zulassung […]
The post Spero Therapeutics-Aktie +300%: Jubelsturm bei NBC-Anlegern! first appeared on sharedeals.de....
|
|
|
28.05.25 - 14:18
|
Pre-market Movers: SPRO, SGBX, BROG, LVWR, CETX. (RTTNews)
|
|
|
Massachusetts-based Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company is up over 224 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading....
|
|
|
|
|
|
|
|
|
28.04.25 - 22:03
|
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu will serve as its President and Chief Executive Officer, effective May 2, 2025, and will be nominated for election as a member of the Board of Directors at Spero's 2025 annual meeting of stockholders. Since January 2025, Ms. Rajavelu has been serving as Spero's Interim President and Chief Executive Officer, and has served as Chief Financial Officer, Treasurer, and Chief Business Officer since November 2023. She will continue to serve as the Company's Chief Financial Officer and Treasurer....
|
|
|
|
|
|
|
|
|
25.02.25 - 16:21
|
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows:...
|
|
|
25.02.25 - 13:03
|
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero's Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference being held in Boston, March 3rd – 5th, 2025. Details are as follows:...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
